858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer Share

– Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated, platinum-resistant ovarian cancer – – Enables access to expedited regulatory review processes, including potential eligibility for accelerated approval and priority review – – Ongoing Phase 1 expansion in BRCA-mutated patients with select solid tumors, including ovarian cancer – SAN… The post 858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer Share appeared first on 8five8 The